Andrew Salzman

Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA.

Children's Hospital Medical Center of Akron provides health care services. It offers primary care, home care, clinical services, surgical services, and financial services. The company is headquartered in Akron, OH.

Lovelace Respiratory Research Institute provides biomedical research services. It conducts research and development of countermeasures to chemical, biological, nuclear, radiological, and explosive emerging and environmental threats to human health as well as advancing the diagnosis and treatment of mental illness and other brain disorders. The company was founded in 1947 and is headquartered in Albuquerque, NM.

RDD Pharma Ltd. develops pharmacological treatments for diseases of the anorectal region. The company was founded by Nir Barak in 2008 and is headquartered in Ramat Hachayal, Israel.

Radikal Therapeutics, Inc. develops transformative pharmaceuticals of bifunctional edox-based small molecules. The company was founded by Andrew L. Salzman and is headquartered in West Tisbury, MA.